Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

The gene editing company has seen its shares surge approximately 160% since mid-June, building on momentum that began after a ...

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...

A new mRNA injection turns immune cells into cancer-fighting CAR-T cells — inside the body. Faster, cheaper, and potentially ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...

In this week’s edition of InnovationRx, we look at the health impact of the Republican spending bill, a startup that built a hospital in India to test its AI software, the impact of the vaccine panel ...